Nasdaq: HGSI) announced today that the company has initiated a Phase 2 clinical trial to examine the safety and preliminary efficacy of repifermin for the treatment of mucositis in patients undergoing chemotherapy for multiple myeloma prior to autologous hematopoietic stem cell transplantation
1) The study was conducted at multiple centers in patients who underwent chemotherapeutic conditioning regimens for autologous hematopoietic stem cell transplantation
Fifty-one of the patients received either placebo or the highest dose of repifermin (75 mcg/kg) intravenously daily for three days prior to their chemotherapeutic conditioning regimen, and daily for seven days following their first autologous hematopoietic stem cell transplantation
Data available on 22 of the 30 patients dosed to date with CG53135 were presented in a poster entitled, "Phase I Trial of CG53135-05 to Prevent Mucositis in Patients Undergoing High-Dose Chemotherapy (HDCT) and Autologous Hematopoietic Stem Cell Transplantation
Francoise Bernaudin, SFGM-TC, France Sunday, 12/08/02, 2:15 pm, Hall C, Oral BMT for Autoimmune Disease Abstract #3409 -- Autologous Hematopoietic Stem Cell Transplantation
in Secondary Progressive Multiple Sclerosis (MS): Clinical, Instrumental Findings and Impact on Quality of Life.